TY - JOUR
T1 - Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment
T2 - A Randomized Clinical Trial
AU - Liu, Wen
AU - Zheng, Deqiang
AU - Li, X.
AU - Wang, T.
AU - Wang, L.
AU - Hao, L.
AU - Ju, M.
AU - Feng, W.
AU - Guo, Z.
AU - Sun, X.
AU - Yu, H.
AU - Qin, Z.
AU - Xiao, Rong
N1 - Publisher Copyright:
© Serdi 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Introduction: To investigate the effect of vitamin D3 (VD3) combined with folic acid (FA) intervention on the cognitive function among patients with mild cognitive impairment (MCI) and vitamin D deficiency. Methods: Our study is a single-center, randomized, controlled trial. A total of 402 patients were randomly assigned to the placebo group (n=135), FA group (n=134), and FA+1600IU VD3 group (n=133). The intervention period was 24 weeks. The primary endpoint was the mean change in Montreal Cognitive Assessment (MoCA) compared to baseline. Secondary endpoints included other cognitive functions, serum vitamin D, folic acid, and homocysteine levels. Results: The Intention-to-Treat analysis results of MoCA showed that the adjusted Least Squares Means (LSM) differences between the FA+1600IU VD3 group and the placebo or FA group were 0.456 (95% CI −0.198 to 1.11; p=0.171) and 0.038 (95% CI −0.600 to 0.676; p=0.907), respectively, and the Per-protocol set analysis results showed that the adjusted LSM differences between the FA+1600IU VD3 group and the placebo or FA group were 0.659 (95% CI 0.005 to 1.313; p=0.048) and 0.251 (95% CI −0.387 to 0.889; p=0.44), respectively. Conclusion: The effect of FA+1600IU VD3 intervention for 6 months on overall cognitive function in MCI patients with vitamin D deficiency was not significant, but its role may be underestimated and requires further long-term studies to confirm.
AB - Introduction: To investigate the effect of vitamin D3 (VD3) combined with folic acid (FA) intervention on the cognitive function among patients with mild cognitive impairment (MCI) and vitamin D deficiency. Methods: Our study is a single-center, randomized, controlled trial. A total of 402 patients were randomly assigned to the placebo group (n=135), FA group (n=134), and FA+1600IU VD3 group (n=133). The intervention period was 24 weeks. The primary endpoint was the mean change in Montreal Cognitive Assessment (MoCA) compared to baseline. Secondary endpoints included other cognitive functions, serum vitamin D, folic acid, and homocysteine levels. Results: The Intention-to-Treat analysis results of MoCA showed that the adjusted Least Squares Means (LSM) differences between the FA+1600IU VD3 group and the placebo or FA group were 0.456 (95% CI −0.198 to 1.11; p=0.171) and 0.038 (95% CI −0.600 to 0.676; p=0.907), respectively, and the Per-protocol set analysis results showed that the adjusted LSM differences between the FA+1600IU VD3 group and the placebo or FA group were 0.659 (95% CI 0.005 to 1.313; p=0.048) and 0.251 (95% CI −0.387 to 0.889; p=0.44), respectively. Conclusion: The effect of FA+1600IU VD3 intervention for 6 months on overall cognitive function in MCI patients with vitamin D deficiency was not significant, but its role may be underestimated and requires further long-term studies to confirm.
KW - Vitamin D
KW - folic acid
KW - mild cognitive impairment
KW - randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85204809098&partnerID=8YFLogxK
U2 - 10.14283/jpad.2024.165
DO - 10.14283/jpad.2024.165
M3 - Article
AN - SCOPUS:85204809098
SN - 2274-5807
VL - 11
SP - 1626
EP - 1633
JO - Journal of Prevention of Alzheimer's Disease
JF - Journal of Prevention of Alzheimer's Disease
IS - 6
ER -